Symbiotec Pharmalab IPO: DRHP Reveals ₹1,507.92 Million In Legal Claims Against Company
New Delhi: The Draft Red Herring Prospectus (DRHP) of Symbiotec Pharmalab showed that the company is facing multiple legal proceedings, including six tax proceedings and one material civil litigation, with the aggregate amount involved against the company standing at Rs 1,507.92 million. Symbiotec Pharmalab’s Rs 1,757 crore initial public offering opened for subscription on Monday and will remain…
The Draft Red Herring Prospectus (DRHP) of Symbiotec Pharmalab revealed that the company is currently facing multiple legal proceedings totaling ₹1,507.92 million. These proceedings include six tax proceedings and one material civil litigation. Symbiotec Pharmalab's initial public offering (IPO), priced between Rs 938-988 per share, opened for subscription on Monday and is set to remain open until August 27.
The pharmaceutical and biotechnology company disclosed one criminal proceeding and six tax proceedings, along with one material civil litigation. Additionally, legal matters involving the company's directors, subsidiaries, and promoters are also being investigated. One of the company's subsidiaries, Knovea Pharmaceutical Private Limited, is currently involved in a civil litigation case before the High Court of Madhya Pradesh regarding land acquired for research and development purposes and a manufacturing facility.
The company cautioned that any unfavorable decisions in these proceedings could have a significant impact on its reputation, management continuity, business operations, results, financial condition, and cash flows.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
